Lornoxicam
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and other musculoskeletal conditions, as well as short-term acute pain. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, reducing the production of prostaglandins responsible for pain and inflammation. It is available as oral tablets and, in some markets, as a powder for solution for injection. Common side effects include nausea, abdominal pain, indigestion, diarrhoea, and dizziness. Important precautions include the risk of gastrointestinal ulcers or bleeding, kidney impairment, fluid retention, and cardiovascular complications, particularly with prolonged use. Lornoxicam should be used at the lowest effective dose for the shortest appropriate duration under medical supervision.
Lornoxicam was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lornoxicam, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Lornoxicam from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lornoxicam, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
